Letter from the CEO of Seelos Therapeutics regarding Trehalose (SLS-005)
- Márcio
- Dec 24, 2023
- 1 min read
Apparently, Seelos Therapeutics fortunately hasn't given up on Trehalose, one of the drugs (SLS-005) in NAF's pipeline for SCA3, seeking FDA approval, and which had its recruitment of *additional* patients halted (including in Brazil) in March 2023 for economic reasons. Seelos' CEO just sent a letter to shareholders.
Excerpt from the letter that Raj Mehra, the CEO of Seelos Therapeutics, sent to shareholders on December 22, 2023, regarding the status of the company and the study on Trehalose (SLS-005) for SCA3 ataxia:
"Additionally, in the SLS-005 program, we began analyzing blinded data from the double-blind, placebo-controlled, Phase IIb/III trial for spinocerebellar ataxias, which, as announced in March 2023, had its additional recruitment (new patients) temporarily paused for economic reasons. Analyzing data for 22 participants over six months of treatment, we found that mean NfL (Neurofilament Light) and m/SARA (Modified Scale for Assessment and Rating of Ataxia) scores appeared to be decreasing, which is not expected for ataxia patients experiencing disease progression. Therefore, the analyzed data suggest that SLS-005 may have a potential (beneficial) effect in these patients."
Seelos' CEO is seeking partners and investors to complete studies of the drugs SLS-002 and SLS-005, and is asking for a shareholder vote to approve the continuation of these efforts.
See Letter at
About SLS-005 (Trehalose)
[Post published on 12/24/2023 by Márcio Galvão]
